SEC
ADPT icon

Seven Eight Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Seven Eight Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,528
Closed -$389K – 543
2021
Q2 		$389K Buy
+9,528
New +$370K 0.05% 459
2020
Q1 		– Sell
-7,000
Closed -$209K – 443
2019
Q4 		$209K Buy
+7,000
New +$201K 0.01% 601

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Seven Eight Capital's ADPT Position: Q3 2021 in Review

Seven Eight Capital sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 9,528 shares — an estimated $389K sold.

Seven Eight Capital first reported a position in ADPT in Q4 2019 and held it in 2 quarters. The position peaked at $389K in Q2 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • Seven Eight Capital reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Seven Eight Capital sold 9,528 Adaptive Biotechnologies shares in Q3 2021, an estimated $389K.
  • Seven Eight Capital first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 2 quarters.
  • Seven Eight Capital's Adaptive Biotechnologies position peaked at $389K in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Seven Eight Capital's 13F filing for Q3 2021, filed 15 Nov 2021.